Quality White Papers & Case Studies

1. FM Approval Standard 4882 9/21/2026

   A fire in a pharmaceutical cleanroom can be contained, but for sterile manufacturers, smoke can turn a localized event into a far wider decontamination, requalification, and production-recovery challenge.

2. Streamline Antibody Analysis For Faster Protein Characterization 9/9/2026

   Strengthen your antibody characterization. Explore approaches for improving sizing accuracy, resolving heterogeneity, and generating reproducible data across demanding biopharmaceutical workflows.

3. The Strategic Value Of In-House Delumping For Homogeneous API Production 9/9/2026

   API batch homogeneity supports efficient manufacturing. Controlled delumping improves powder flow and chargeability while maintaining particle size integrity and reducing GMP-scale risks.

4. Enhancing Quality And Environmental Monitoring Efficiency Through Paperless Sampling 9/9/2026

   At roughly 600,000 samples per year, manual EM documentation creates real compliance and operational risk. This whitepaper details how a fully integrated digital sampling system addresses both.

5. Planning And Installing An Environmental Monitoring System 9/9/2026

   Transitioning to automated environmental monitoring requires structured planning, proper tubing and sensor setup, and robust GAMP validation to ensure cleanroom regulatory compliance.

6. Trend Analysis Of Particle Monitoring Data And Defining Alert And Action Limits 9/9/2026

   Routine trend analysis of total and viable particle monitoring data helps identify operational shifts early, set statistical limits, and strengthen cleanroom contamination control strategies.

7. Active Air Sampler Comparison In Remote Settings 9/9/2026

   Discover how optimized air sampler geometry improves microbial collection efficiency and continuous environmental monitoring accuracy to safeguard critical cleanroom operations.

8. Digital CMC Maturity: Rethinking QTTP And Control Strategy 9/2/2026

   Digital CMC maturity depends on structured, science- and risk-based knowledge. Learn how connecting development, validation, regulatory, and lifecycle information can accelerate timelines.

9. Beyond Protein A: Efficient Purification Strategies For Misbehaving mAbs 9/1/2026

   Next-generation antibody formats require more precise purification strategies. Explore how subdomain-specific VHH ligands can address structural heterogeneity, improve purity, and preserve stability.

10. Robust Database Characterizes And Optimizes Product Development 8/29/2026

    Integrating material characterization data with process parameters accelerates drug development, reduces empirical testing, and strengthens regulatory compliance.